May 17, 2018Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe autoimmune
diseases and cancer, today announced that Chief Executive Officer, Tim Van
Hauwermeiren, will present at several upcoming investor conferences:
* UBS 2018 Global Healthcare Conference. Company presentation on Tuesday, May
22, 2018 at 2:00 p.m. ET in New York City.
* Jefferies 2018 Global Healthcare Conference. Company presentation on
Wednesday, June 6, 2018 at 1:30 p.m. ET in New York City.
* JMP Securities Life Sciences Conference. Panel discussion on Wednesday, June
20, 2018 at 10:30 a.m. ET in New York City.
Live webcasts of the UBS and Jefferies presentations will be available on the
Company's website at www.argenx.com. Replays of the webcasts will be available
for 90 days following the presentation.
argenx is a clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe auto-immune
diseases and cancer. We are focused on developing product candidates with the
potential to be either first-in-class against novel targets or best-in-class
against known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this focus is enabled
by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform,
based on the powerful llama immune system, allows us to exploit novel and
complex targets, and our three antibody engineering technologies are designed to
enable us to expand the therapeutic index of our product candidates.
For further information, please contact:
Joke Comijn, Corporate Communications & IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
The contents of this announcement include statements that are, or may be deemed
to be, "forward-looking statements." These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates," "expects," "intends," "may," "will," or
"should," and include statements argenx makes concerning the intended results of
its strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. argenx's actual results may differ
materially from those predicted by the forward-looking statements as a result of
various important factors, including argenx's expectations regarding its the
inherent uncertainties associated with competitive developments, preclinical and
clinical trial and product development activities and regulatory approval
requirements; argenx's reliance on collaborations with third parties; estimating
the commercial potential of argenx's product candidates; argenx's ability to
obtain and maintain protection of intellectual property for its technologies and
drugs; argenx's limited operating history; and argenx's ability to obtain
additional funding for operations and to complete the development and
commercialization of its product candidates. A further list and description of
these risks, uncertainties and other risks can be found in argenx's U.S.
Securities and Exchange Commission (SEC) filings and reports, including in
argenx's most recent annual report on Form 20-F filed with the SEC as well as
subsequent filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as of
the date of publication of this document. argenx undertakes no obligation to
publicly update or revise the information in this press release, including any
forward-looking statements, except as may be required by law.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: argenx SE via GlobeNewswire
© InPublic, source European Press Releases